StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
PPCBPropanc Biopharma, Inc.
stockpulse.co.kr
Nasdaq
$0.2795▼ 0.89%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $636,804.97Shares out 2.3M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 4d agoPre-market26.10.21 22:23
    DEF 14COther#●●●#●●●

    Propanc Biopharma, Inc.

    Propanc Biopharma has approved a reverse stock split of its common stock at a ratio between 1:2 and 1:10 via board and majority shareholder written consent. The action is intended to maintain the company's financing and capital-raising capabilities, reducing the 10,331,116 shares outstanding as of October 8, 2026, to between approximately 5,165,558 and 1,033,112 shares.…more

    $0.2795-0.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.8After-hours26.10.09 06:25
    PRE 14COther

    Propanc Biopharma, Inc.

    Propanc Biopharma has approved a reverse stock split of its common stock at a ratio between 1:2 and 1:10, authorized by the Board and majority shareholders. The action is intended to maintain the company's financing and capital-raising capabilities, reducing the 10,331,116 shares outstanding as of October 8, 2026, to between approximately 5,165,558 and 1,033,112 shares.…more

    $0.2795-0.89%vs prev close
    View filingShare
  • 10.5After-hours26.10.06 06:15
    S-1Offering

    Propanc Biopharma, Inc.

    Propanc Biopharma has filed an S-1 registration statement for the resale of 6,500,000 shares of common stock issuable upon the conversion of Series C Preferred Stock. This filing facilitates the conversion and potential resale of shares by the existing preferred stockholder.…more

    $0.2795-0.89%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 2d agoAfter-hours26.10.23 05:24
    Bullish#●●●#●●●

    Propanc Biopharma Implements 1-for-10 Reverse Stock Split to Maintain Nasdaq Listing…more

    Propanc Biopharma is executing a 1-for-10 reverse stock split to meet Nasdaq's minimum bid price requirement and maintain its listing. The company states this action is intended to support future growth plans and upcoming R&D milestones.…more

    $0.2795-0.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 3d agoPre-market26.10.22 21:30

    ●●●●●●●● ●●●●● ●●●●●●

    Propanc Biopharma is executing a 1-for-10 reverse stock split to comply with Nasdaq's minimum bid price requirement and maintain its listing. This corporate action adjusts the share count without changing the company's fundamental valuation.…more

    $0.2795-0.89%vs prev close
    Read sourceShareGlobeNewswire
  • 10.16Pre-market26.10.16 21:36

    ●●●●●●●● ●●●●● ●●●●●●

    Propanc Biopharma reported that its lead candidate, PRP, successfully reprogrammed chemotherapy-resistant pancreatic cancer cells to restore therapeutic sensitivity in preclinical studies. As these findings are based on early-stage research, further clinical validation is required to confirm therapeutic efficacy.…more

    $0.2795-0.89%vs prev close
    Read sourceShareGlobeNewswire

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →